How MedTech Companies Drive Product Commercialization Through CDMO Partnerships

Over the past two years, revisions to key regulations by the National Medical Products Administration (NMPA) have had a profound impact on contract manufacturing of medical devices.

On June 1, 2021, the newly revised Regulations on the Supervision and Administration of Medical Devices officially came into effect, marking the formal inclusion of the Marketing Authorization Holder (MAH) system for medical devices into the government’s regulatory framework. The MAH system “decouples” medical device registration from production, enabling the model of “prototype development coupled with outsourced large-scale manufacturing.” This addresses key industry pain points, such as high upfront capital investment, lengthy product commercialization cycles, difficulties in recruiting specialized talent, and underutilization of facilities and infrastructure. Furthermore, it helps medical device companies ensure full lifecycle support at a lower cost, improve product quality, anticipate and mitigate compliance risks, and expand production capacity.

For medical device companies, these changes also raise new questions: How exactly do CDMOs drive product commercialization? And how can companies select the right device CDMO for their products?

To address these questions, from 20:00 to 21:30 on November 15, 2022,VCBeat SelectJoin HandsMediThink, co-hosting an online live public lecture. This course will focus on"How Can Medical Device Companies Drive Product 'Translation' Through CDMOs?"Sharing the Full Process of How CDMOs Help Medical Device Companies Achieve Product Commercialization

Not only that, this session also invitesLin Senyong, President of the Shanghai Yangtze River Delta Medical Device Industry Development Promotion AssociationandLi Tianmin, CEO of Weimai Medical, participate together【Medical Device CDMO: How to Choose One That Truly Empowers and Accelerates Enterprise Growth?】Roundtable Discussion: Helping Enterprises Understand and Select the Right CDMO

The first 20 viewers to participate in the live stream interaction will also receive a complimentary benefit from Medisino: [Expert Free Assessment for Entrusted CDMO Service Products]. The assessment covers market research, feasibility studies, project costs, timelines, and more. Consult our assistant to enjoy a 15% discount when signing up for CDMO services.Scan the QR code in the poster below to register for the live stream:

1. Impact of Regulatory Revisions in the Past Two Years on Contract Manufacturing Operations for Medical Devices;

2. Conditions, Rights, and Obligations of the Entrusting Party and the Entrusted Party;

3. How to Drive the “Translation” of Medical Device Products Through CDMOs.

Medical Device Enterprises with R&D Capabilities and Technical PatentsFounder & General Manager

[Recommendation: ★★★★★]

Heads of R&D, Quality Systems, and Production at Medical Device Companies

[Recommendation: ★★★★]

Clinical institutions or experts seeking to commercialize technological achievements, R&D teams from research institutes, etc.

[Recommendation: ★★★]

If you belong to the above-mentioned groups or have products in urgent need of commercialization, be sure not to miss this information-packed open lecture.

Lin Senyong|President of the Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association; China Chamber of Commerce for Import and Export of Medicines and Health Products, International Cooperation in Medical DevicesExecutive President of the Branch

Formerly Director of the Medical Device Supervision Division at the Shanghai Municipal Medical Products Administration, he currently serves as President of the Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association and Chairman of the Medical Device International Cooperation Branch of the China Chamber of Commerce for Import and Export of Medicines and Health Products. With 21 years of experience in the drug regulatory system, he has long been engaged in medical device supervision and the research, formulation, and revision of policies and regulations. He participated in the drafting and revision of the National Regulations on the Supervision and Administration of Medical Devices and its supporting rules across three major updates, contributed to the formulation of Shanghai’s medical device industrial policies and the 14th Five-Year Plan, and was one of the principal designers and drafters of China’s Medical Device Registrant System.

Li Tianmin | CEO, Weimai Medical

CEO of Weimai Medical, holds a Master’s degree in In Vivo Drug Analysis from China Pharmaceutical University and a Ph.D. in Molecular Biology from the University of Nebraska and Columbia University. Previously held positions at Johnson & Johnson China, Bayer Pharma (Germany), CanRui Hao, and Huafu Bio, with extensive experience in market positioning for new products and regulatory submissions for market launch. Within just two years, facilitated angel, Pre-A, and Series A financing rounds for employing companies, and led the team to incubate the world’s first repair technology system in the field of medical aesthetics.

He Ping | Chairman and General Manager of Medisun

Previously held positions at renowned enterprises such as Jetong Group and China Resources Medical. Possesses nearly a decade of experience in regulatory registration and market expansion for medical devices in China and overseas, with expertise in strategic planning and management for the pre-market launch of high-risk and innovative medical device products. Maintains extensive resources in government relations, clinical institutions, and capital markets, demonstrating strong capabilities in forecasting and navigating market dynamics.